Cryoport Q1 revenue rises

CryoPort

04/05/2026 21:28

Overview

U.S. temperature-controlled supply chain firm's Q1 revenue rose 16% yr/yr to $47.8 mln

Company raised full-year revenue guidance to $192 mln-$196 mln

Adjusted EBITDA loss narrowed by $2.2 mln yr/yr, reflecting improved operational discipline

Outlook

Cryoport raises full-year 2026 revenue guidance to $192 mln-$196 mln

Company expects BioServices launch in Paris in Q3 and new Santa Ana center in Q4

Cryoport anticipates multiple growth catalysts, including new therapy approvals and facility expansions

Result Drivers

CGT PROGRAM EXPANSION - Revenue from commercial cell and gene therapy programs grew 26% yr/yr, reflecting continued expansion in approved therapies

STRONG PRODUCT DEMAND - Life Sciences Products revenue rose 15% yr/yr, driven by global demand for cryogenic systems

INTEGRATED SERVICES GROWTH - Life Sciences Services revenue increased 18% yr/yr, led by 21% growth in BioStorage/BioServices

Company press release: ID:nPnc8fn90a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$10.54 mln
Q1 Gross Margin
45.80%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

Wall Street's median 12-month price target for Cryoport Inc is $14.00, about 35.3% above its May 1 closing price of $10.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)